Rallybio Corporation announced that an abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting, which will be held December 9-12, 2023, in San Diego, California. Details of the poster presentation are as follows: Identifying Pregnancies at Higher Risk for HPA-1a Alloimmunization and Fetal/Neonatal Alloimmune Thromssocytopenia (F NAIT): An International, Prospective, Natural History Study.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | +6.21% | -10.47% | -28.45% |
May. 15 | JPMorgan Downgrades Rallybio to Neutral From Overweight | MT |
May. 09 | Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.45% | 66.73M | |
+64.23% | 55.07B | |
-2.31% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.97% | 26.28B | |
-21.16% | 18.93B | |
+7.54% | 13.03B | |
+27.17% | 12.26B | |
+25.72% | 12.21B |
- Stock Market
- Equities
- RLYB Stock
- News Rallybio Corporation
- Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting